Evidence map›Paper›PMID 35991830›Full record

ArticleCanadian liver journal2019

Circulating and inducible IL-32α in chronic hepatitis C virus infection.

Mark Collister, Julia Rempel, Jiaqi Yang, Kelly Kaita, Zach Raizman, Yuwen Gong, Gerald Minuk

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian liver journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 64% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mark CollisterSection of Hepatology, University of Manitoba, College of Medicine, Winnipeg, Manitoba.
Julia RempelSection of Hepatology, University of Manitoba, College of Medicine, Winnipeg, Manitoba.
Jiaqi YangSection of Hepatology, University of Manitoba, College of Medicine, Winnipeg, Manitoba.
Kelly KaitaSection of Hepatology, University of Manitoba, College of Medicine, Winnipeg, Manitoba.
Zach RaizmanSection of Hepatology, University of Manitoba, College of Medicine, Winnipeg, Manitoba.
Yuwen GongSection of Hepatology, University of Manitoba, College of Medicine, Winnipeg, Manitoba.
Gerald MinukSection of Hepatology, University of Manitoba, College of Medicine, Winnipeg, Manitoba.
University of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Interleukin 32 (IL-32) is a recently described pro-inflammatory cytokine implicated in chronic hepatitis C virus (HCV)-related inflammation and fibrosis. IL-32α is the most abundant IL-32 isoform. Methods: Circulating IL-32α levels were documented in patients with chronic HCV infections ( Results: Circulating IL-32α levels in patients with chronic HCV were similar to those of spontaneously resolved and HCV-naive controls. HCV protein induced IL-32α responses were similar in chronic HCV patients and HCV-naive controls. In patients with chronic HCV, serum IL-32α levels correlated with worsening METAVIR fibrosis (F) scores from F0 to F3 ( Conclusions: IL-32α activity is associated with worsening fibrosis scores in non-cirrhotic, chronic HCV patients.

Indexed as

core and NS3 proteinfibrosishepatitis C virusIL-32α

Identifiers

PMID35991830
PMCPMC9202682
OpenAlexW4252289129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.